Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P=0.016). Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:372 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 372(2015), 25, Seite 2387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braunwald, Eugene [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1056/NEJMoa1410489 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1969950668 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1969950668 | ||
| 003 | DE-627 | ||
| 005 | 20230513204619.0 | ||
| 007 | tu | ||
| 008 | 160211s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1410489 |2 doi | |
| 028 | 5 | 2 | |a PQ20160211 |
| 035 | |a (DE-627)OLC1969950668 | ||
| 035 | |a (DE-599)GBVOLC1969950668 | ||
| 035 | |a (PRQ)c2205-3180e269bd2b848db2bfd7fcb2ee71bf54aabd188e82508d0f02c8c4a4ab12a0 | ||
| 035 | |a (KEY)0171808820150000372002502387ezetimibeaddedtostatintherapyafteracutecoronarysyn | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Braunwald, Eugene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years. The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P=0.016). Rates of prespecified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.). | ||
| 650 | 4 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | |
| 650 | 4 | |a Cardiovascular Diseases - mortality | |
| 650 | 4 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | |
| 650 | 4 | |a Cardiovascular Diseases - epidemiology | |
| 650 | 4 | |a Azetidines - adverse effects | |
| 650 | 4 | |a Triglycerides - blood | |
| 650 | 4 | |a Anticholesteremic Agents - therapeutic use | |
| 650 | 4 | |a Azetidines - therapeutic use | |
| 650 | 4 | |a Cholesterol, LDL - blood | |
| 650 | 4 | |a Anticholesteremic Agents - adverse effects | |
| 650 | 4 | |a Acute Coronary Syndrome - drug therapy | |
| 650 | 4 | |a Simvastatin - therapeutic use | |
| 650 | 4 | |a Cardiovascular Diseases - prevention & control | |
| 650 | 4 | |a Drug therapy, Combination | |
| 650 | 4 | |a Simvastatin | |
| 650 | 4 | |a Analysis | |
| 650 | 4 | |a Drug therapy | |
| 650 | 4 | |a Acute coronary syndrome | |
| 650 | 4 | |a Dosage and administration | |
| 650 | 4 | |a Practice guidelines (Medicine) | |
| 650 | 4 | |a Usage | |
| 650 | 4 | |a Pharmaceuticals | |
| 650 | 4 | |a Acute coronary syndromes | |
| 650 | 4 | |a Statins | |
| 700 | 1 | |a De Ferrari, Gaetano M |4 oth | |
| 700 | 1 | |a Cannon, Christopher P |4 oth | |
| 700 | 1 | |a Bohula, Erin A |4 oth | |
| 700 | 1 | |a Blazing, Michael A |4 oth | |
| 700 | 1 | |a Jukema, J Wouter |4 oth | |
| 700 | 1 | |a Ruzyllo, Witold |4 oth | |
| 700 | 1 | |a Darius, Harald |4 oth | |
| 700 | 1 | |a Theroux, Pierre |4 oth | |
| 700 | 1 | |a Tershakovec, Andrew M |4 oth | |
| 700 | 1 | |a Musliner, Thomas A |4 oth | |
| 700 | 1 | |a Giugliano, Robert P |4 oth | |
| 700 | 1 | |a Reist, Craig |4 oth | |
| 700 | 1 | |a Im, KyungAh |4 oth | |
| 700 | 1 | |a De Lucca, Paul |4 oth | |
| 700 | 1 | |a Ophuis, Ton Oude |4 oth | |
| 700 | 1 | |a Wiviott, Stephen D |4 oth | |
| 700 | 1 | |a Lewis, Basil S |4 oth | |
| 700 | 1 | |a Califf, Robert M |4 oth | |
| 700 | 1 | |a McCagg, Amy |4 oth | |
| 700 | 1 | |a White, Jennifer A |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 372(2015), 25, Seite 2387 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:372 |g year:2015 |g number:25 |g pages:2387 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1056/NEJMoa1410489 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26039521 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1689866542 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_287 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2012 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 372 |j 2015 |e 25 |h 2387 | ||